Recursion Pharmaceuticals Inc Class A RXRX
News
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
Recursion to Participate in Upcoming Investor Conferences
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
